GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (NAS:VBIV) » Definitions » Cyclically Adjusted PS Ratio

VBI Vaccines (VBI Vaccines) Cyclically Adjusted PS Ratio : 1.08 (As of May. 28, 2024)


View and export this data going back to 2016. Start your Free Trial

What is VBI Vaccines Cyclically Adjusted PS Ratio?

As of today (2024-05-28), VBI Vaccines's current share price is $0.64. VBI Vaccines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.59. VBI Vaccines's Cyclically Adjusted PS Ratio for today is 1.08.

The historical rank and industry rank for VBI Vaccines's Cyclically Adjusted PS Ratio or its related term are showing as below:

VBIV' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.85   Med: 117.78   Max: 384.38
Current: 1.09

During the past years, VBI Vaccines's highest Cyclically Adjusted PS Ratio was 384.38. The lowest was 0.85. And the median was 117.78.

VBIV's Cyclically Adjusted PS Ratio is ranked better than
84.62% of 507 companies
in the Biotechnology industry
Industry Median: 5.5 vs VBIV: 1.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

VBI Vaccines's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.049. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.59 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


VBI Vaccines Cyclically Adjusted PS Ratio Historical Data

The historical data trend for VBI Vaccines's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines Cyclically Adjusted PS Ratio Chart

VBI Vaccines Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.36 122.88 113.23 19.92 0.99

VBI Vaccines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.49 5.62 1.09 0.99 1.01

Competitive Comparison of VBI Vaccines's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, VBI Vaccines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VBI Vaccines's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VBI Vaccines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where VBI Vaccines's Cyclically Adjusted PS Ratio falls into.



VBI Vaccines Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

VBI Vaccines's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.64/0.59
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VBI Vaccines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, VBI Vaccines's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.049/131.7762*131.7762
=0.049

Current CPI (Mar. 2024) = 131.7762.

VBI Vaccines Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.227 100.392 0.298
201512 -0.016 99.792 -0.021
201603 0.076 100.470 0.100
201606 0.089 101.688 0.115
201609 0.233 101.861 0.301
201612 0.110 101.863 0.142
201703 0.095 102.862 0.122
201706 0.257 103.349 0.328
201709 0.144 104.136 0.182
201712 0.107 104.011 0.136
201803 0.083 105.290 0.104
201806 0.109 106.317 0.135
201809 0.121 106.507 0.150
201812 1.154 105.998 1.435
201903 0.111 107.251 0.136
201906 0.197 108.070 0.240
201909 0.184 108.329 0.224
201912 0.096 108.420 0.117
202003 0.070 108.902 0.085
202006 0.025 108.767 0.030
202009 0.038 109.815 0.046
202012 0.020 109.897 0.024
202103 0.036 111.754 0.042
202106 0.017 114.631 0.020
202109 0.013 115.734 0.015
202112 0.009 117.630 0.010
202203 0.015 121.301 0.016
202206 0.040 125.017 0.042
202209 0.037 125.227 0.039
202212 0.034 125.222 0.036
202303 0.056 127.348 0.058
202306 0.084 128.729 0.086
202309 0.313 129.860 0.318
202312 0.036 129.419 0.037
202403 0.049 131.776 0.049

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


VBI Vaccines  (NAS:VBIV) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


VBI Vaccines Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


VBI Vaccines (VBI Vaccines) Business Description

Industry
Traded in Other Exchanges
Address
160 Second Street, Floor 3, Cambridge, MA, USA, 02142
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Executives
Steven Gillis director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Robert Dillman officer: Chief Commercial Officer C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3, CAMBRIDGE MA 02142
Nell Beattie officer: Director, Corp Development/IR 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Damian Braga director 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Francisco Diaz-mitoma officer: Chief Medical Officer 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Christopher Mcnulty officer: CFO and Head of BD C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeff Baxter director, officer: President and CEO C/O VBI VACCINES INC.,, 222 THIRD STREET, STE 2241, CAMBRIDGE MA 02142
Joanne Cordeiro director 171 SWANTON STREET, UNIT 48, WINCHESTER MA 01890
Blaine H. Mckee director C/O HART, 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

VBI Vaccines (VBI Vaccines) Headlines